DaVita Clinical Research Campaign Shares Stories from Participants and Researchers
DaVita Clinical Research launched its "Inspired to Give" campaign
DaVita Clinical Research® launched its “Inspired to Give” campaign, which started November 12 and runs through February 2014, features both clinical trial participants and researchers sharing their personal experiences with clinical research. The series utilizes video, Instagram and Twitter to spread the word. The campaign asks individuals to share what inspires them to give to the medical community and humankind through participation in clinical trials.
“We find that the driving force for most who participate in clinical trials is that they have someone close to them who has a disease or illness and they want to help that person,” said DCR Chief Scientific Officer Dr. Harry Alcorn. “And in additional to being altruistic, trial participants ultimately play a key role in the future of health care by helping to develop medicine for others.”
You can read the full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
